The American Association of Clinical Endocrinology (AACE) recommends the consideration of the potential benefits of SGLT2 in patients with type 2 diabetes and MASLD, as it may reduce hepatic steatosis while offering cardiac and renal effects. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.